Efficacy and safety of Ipragliflozin in patients with type 2 diabetes who have inadequate glycemic control.
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000014306
- Lead Sponsor
- akakinen clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Type-1 diabetes, diabetes due to a pancreatic disorder, or secondary diabetes due to conditions (2) Application of contraindications contained in the package insert (3) Severe renal function disorder (4 )BMI is < 22kg/m2 (5) Under treatment with insulin,GLP-1 analog,or SGLT-2 inhibitor (6) Pregnant women, women suspected of being pregnant, or lactating women (7) Participation in the study is judged by the investigator or sub-investigator as inappropriate for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in Glycosylated hemoglobin (HbA1c) levels over 6 months.
- Secondary Outcome Measures
Name Time Method 1) Change in fasting blood glucose, body weight, waist circumference, IRI, serum lipid and body composition over 6 months. 2)CGM